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Summary 
Inbred mice exhibit a spectrum of susceptibility to induction of experimental allergic encepha- 
lomyelitis (EAE). We have compared the immune responses of the susceptible SJL (H-29 and 
resistant  B10.S  (H-2  S)  strains  to  determine  factors other  than  the  MHC  background  which 
control resistance/susceptibility to EAE. The resistance of the B10.S strain was found to be sec- 
ondary to an antigen-specific defect in the generation of Thl cells that produce IFN% This de- 
fect in IFN~/ production  could be restored by exposure of the myelin basic protein  (MBP)- 
reactive T  cells to IL-12 with the subsequent induction of the ability to transfer EAE to naive 
recipients. These findings have important implications for the therapeutic use oflL-12 and IL-12 
antagonists and may explain the association between relapses/exacerbation ofautoimmune dis- 
ease and infectious diseases. 
E 
AE  is  a  demyelinating  disease  of the  central  nervous 
system  induced  by  an  autoimmune  response  against 
myelin  proteins,  particularly  myelin basic  protein  (MBP) 
and  its  derivative  peptides  (1-3).  EAE  is  mediated  by 
CD4+  T  cells and the T  cells responsible for disease  induc- 
tion produce  Thl  type cytokines.  Thus,  MBP-reactive T 
cell  clones  and  lines  that  are  encephalitogenic  have been 
found to produce either IFN% TNFoL, or TNF[~ or a com- 
bination of these cytokines, while T  cell clones or lines that 
produce  IL-4  or  IL-10  are  non-encephalitogenic  (4-8). 
Exposure of MBP-reactive  LN cells  to  IL-12,  a powerful 
inducer of IFN',/, enhances their encephalitogenicity. Con- 
versely, treatment of animals that have received MBP-reac- 
tive  cells  with  neutralizing  antibodies  to  IL-12 attenuates 
the  symptomatology of EAE  (9).  Examination  of spinal 
cords  from diseased  animals  has  revealed the  presence  of 
mRNA for IFN"/and TNF during clinical  episodes, whereas 
mRNA  for IL-10 appeared at the  time  of clinical  remis- 
sions (10).  This suggests that remissions may be induced by 
downregulation  of the Thl  response by the production of 
Th2-type cytokines. Furthermore, EAE can be ameliorated 
by the infusion of either IL-4 or IL-10 (11-12). 
Inbred strains of mice exhibit a spectrum of susceptibility 
to induction of EAE. The MHC plays a critical role in dis- 
ease  susceptibility  and  strains  bearing  H2  s or  H2  u haplo- 
types have been found to be susceptible, while those bear- 
ing H2  a or H2  k are resistant.  One important exception is 
the B10.S strain, which is resistant to both active and pas- 
sive EAE despite bearing the same MHC  (H2  9  as mice of 
the  prototypical susceptible strain,  SJL  (13).  In this paper, 
we  compare the  immune responses of the  SJL and B10.S 
strains to MBP  in an attempt to uncover factors that may 
control resistance/susceptibility to EAE. As the differential 
induction  of a Thl  vs a Th2 response has been shown to 
critically influence both the immune responses of different 
mouse  strains  to  infection by pathogens  and the  immune 
responses  needed  for  induction  of autoimmune  diseases 
(14-16),  we have focused our efforts on  a comparison of 
cytokine  production  by the  two  strains.  We  demonstrate 
that the  resistance of the B10.S  strain  to the  induction  of 
EAE after immunization with MBP is secondary to an anti- 
gen-specific defect in the generation of Thl  cells that pro- 
duce IFN',/. However, the defect in IFN~ production can 
be corrected by exposure  of the  MBP-reactive T  cells  to 
IL-12 in vitro with the subsequent induction of encephali- 
togenic  T  cells.  These results have important implications 
for furthering our understanding of the role of cytokines in 
the susceptibility  to, and pathogenesis of, autoimmune disease. 
Materials  and Methods 
Mice.  Female  B10.S  and  SjL/j  mice  were  obtained  from 
McLaughlin  Research  Institute  (Great  Falls, MT)  and Jackson 
Laboratory  (Bar Harbor, ME), respectively, and kept in a patho- 
gen free facility. All mice were 8-12 wk of age when experiments 
were initiated. 
Antigens.  MBP was prepared from guinea pig spinal cords, as 
previously  described  (17), Peptides  corresponding  to  residues 
260-283  of Influenza  A  nucleoprotein  (NP260_28> ARSALIL- 
RGSVAHKSCLPACVYGP),  and  residues  87-106  of  MBP 
(MBPs:_m6, VVHFFKNIVTPRTPPPSQGK)  were  synthesized 
and purified by HPLC by the Laboratory of Molecular Structure, 
Peptide Synthesis Laboratory (NIAID, NIH, Bethesda, MD). 
Immunization.  Mice were immunized subcutaneously at four 
sites over the flanks with an emulsion  containing  equal volumes 
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in PBS. Each mouse received a total of 0.1 ml of emulsion (0.025 
ml/site) containing 30 lag of Mycobacterium tuberculosis and an 
optimal dose of the relevant antigen. Optimal doses were deter- 
mined in pilot experiments as follows: MBP,  400  lag; NP2~0_283, 
5 txg; MBP87_I06, 100 lag. 
Generation qf Ag-Spec!fic LN Cells  for Cell Transfer and Analysis of 
Cytokine Production.  10-11  d  after immunization  draining LN 
cells (inguinal and axillary) were removed and processed as previ- 
ously described. Cells were cultured in RPMI  1640  containing 
10%  FCS  and  standard  supplements  (18)  with  either  MBP 
(25 lag/ml),  MBP87_10(, (50  ~g/ml),  or NP260_2s  3 (12.5  lag/ml). 
Supernatants were removed at 24 h intervals for quantification of 
cytokine levels.  After four days  of culture,  cells were harvested 
and washed extensively. Some of these cells were injected into 
naive  recipients  (35  X  106  cells/mouse intraperitoneal) to  test 
their  encephalitogenicity. Other  cells  were  recultured  in  fresh 
medium with or without soluble antigen and supernatants were 
removed at 24 and 48 h for cytokine analysis. 
Where  specified,  cytokines  or  neutralizing antibodies  were 
added to the primary cultures as follows: IL-12, 20 ng/ml (gift of 
S. Wolf, Genetics Institute, Cambridge, MA); anti-IL-4 mAb, 10 
btg/ml (clone 11Bll; gift of W.E. Paul, NIAID, NIH); rat anti- 
mouse  IL-10  mAb,  0.5  lag/ml  (clone JES5-2A5;  PharMingen, 
San Diego, CA); recombinant murine IFN',/, 30 ng/ml (Pharm- 
ingen); and anti-mouse IFNT, 20 lacg/ml (clone XMG  1.2; gift 
ofR. Seder, NIAID, NIH). 
Pur!fication of T Cells.  T cells were purified to levels of'-'90% 
purity from LN cell preparations by passage through nylon wool 
columns followed by "mouse T cell enrichment" columns (R & D 
Systems,  Minneapolis,  MN).  Recovered  T  cells  were  washed 
twice, resuspended in complete medium at  1  X  106  cells/well, 
and  then  cocultured  with  irradiated  (3,000  rads)  splenocytes 
added at a  1:4  ratio. Before being added,  splenocytes were  de- 
pleted of T  cells by c-mediated lysis using anti-Thy 1.2  (present 
in supernatants of cell line HO13.4-9). 
Proliferation Assays.  LN cells (5  X  105/0.2  ml) were cultured 
with various concentrations of antigen or with media alone for 4 d 
in 96-weU round-bottom plates (Costar,  Cambridge, MA) at 37~ 
in 3%  CO2-air. Wells were pulsed for the final 16 h  of culture 
with  1 laCi of [3H]TdR  (Amersham Corp., Arlington Heights, 
IL) and counted as previously described (18). 
Cytokine ELISA.  Cytokines  were  quantified  using  a  sand- 
wich ELISA technique based on noncompeting pairs of antibod- 
ies. The capture and detection mAbs used for each cytokine were 
obtained from PharMingen  except for rabbit anti-mouse IFNy 
(Spring Valley Laboratories, Woodbine, MD).  Goat anti-rabbit 
lgG-HRP  (Southern  Biotechnology Associates, Inc.,  Birming- 
ham, AL) was used as a tertiary Ab in the IFN'y ELISA. Peroxi- 
dase labeled streptavidin (Kirkegaard & Perry Laboratories, Inc., 
Gaithersburg, MD) was applied as a last step in the ELISAs using 
biotinylated detection  antibodies.  Plates  were  developed  with 
TMB peroxidase substrate (Kirkegaard & Perry) and stopped with 
10% sulfuric acid. 
Clinical Evaluation.  After injection of MBP-reactive cells, mice 
were examined daily for signs ofneurologic impairment and rated 
for severity of symptomatology as previously described (18). 
Results 
BIO.S Mice Have A  Specific Defect  in  IFNT Production  in 
Response to MBP.  As an initial approach to determine the 
basis of the  resistance  of B10.S  mice  to  EAE,  we  immu- 
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Figure 1.  MBP-reactive  LN cells  from B10.S mice proliferate,  but do not 
produce IFN',/ on antigenic challenge in vitro. Draining LN cells from 
MBP-primed B10.S (closed symbols) or SJL (open symbols) mice were stim- 
ulated in vitro with MBP (circles)  or PPD (diamonds). Proliferative  responses 
(A) were measured after 96 h and IFN~ production assayed over a 96-h 
period (/3). Draining LN cells  from B10.S and SJL mice primed with MBP 
(C) or with the peptide, MBP87_,,,, (D) were cultured for 96 h with MBP 
or with MBP87_l~u, respectively,  washed, restimulated  for 48 h with antigen, 
and IFNy production measured. Results are representative  of 10 experiments 
each using LN cells pooled from five or more mice. nd, none detected. 
nized B10.S  and  SJL mice  with  guinea pig MBP  in  CFA 
and compared the proliferative responses and cytokine pro- 
duction  of draining LN  cells to  antigen  stimulation  10  d 
later.  LN  cells from  the  two  strains  mounted  comparable 
proliferative responses to MBP and to PPD  (Fig.  1 A) and 
produced comparable quantities of IL-2 in an antigen-spe- 
cific manner  (data  not  shown).  However,  LN  cells from 
SJL  mice  produced  significant  quantities  of IFN'y which 
accumulated  over time,  while  LN  cells from  B10.S  mice 
failed to secrete detectable quantities of that cytokine (Fig. 
1 B). Furthermore, LN cells from B10.S mice failed to pro- 
duce significant amounts of IFNy upon secondary in vitro 
stimulation, while LN cells from SJL produced heightened 
amounts  of  IFNy  with  accelerated  kinetics  (Fig.  1  C). 
TNFcl production was not detectable in LN cells of either 
strain (data not shown). 
The failure of the B10.S mice to produce 1FN'y was not 
related to the overproduction of suppressive Th2 cytokines 
as  LN  cells  from  neither  strain  produced  detectable 
amounts oflL-4 or IL-10 (data not shown), nor did the ad- 
dition of anti-IL-4 or anti-IL-10 alone or in combination 
to primary cultures restore the capacity of B10.S T  cells to 
produce IFN'y on secondary in vitro stimulation with MBP 
(see Fig. 3).  Furthermore, treatment of B10.S animals dur- 
ing the course of priming with MBP  with large quantities 
of a  neutralizing anti-IL-4 mAb  (0.5  mg of 11B1 1  intra- 
peritoneal on day 0, 3, and 7) failed to result in IFN~ pro- 
duction  upon  stimulation  of the  LNC  in  vitro  (data  not 
shown). The defect was also not related to a failure of pro- 
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Figure 2.  The failure of MBP-primed B10.S T cells to produce IFN~/ 
in vitro is antigen-specific. LNCs from NP260_283-primed (closed  squares) or 
MBP-primed (open circles) B10.S mice were stimulated for 96 h in vitro 
with antigen and IFN3~ levels were measured at 24-h intervals (A). The 
cultures were then washed and restimulated for 48 h and IFN~/ produc- 
tion assayed (B). Kesults are representative of seven experiments each us- 
ing LN cells pooled from five or more mice. 
cessing or presentation  of the  encephalitogenic  epitope  of 
MBP as similar results were obtained after immunization of 
the two strains with the encephalitogenic peptide, MBP87_t06 
(Fig. 1 D). In addition, the inability ofMBP-reactive B10.S 
T  cells to produce IFN'y was not secondary to a defect in 
cytokine production by B10.S APC. The capacity of puri- 
fied MBP-specific B10.S T  cells to produce IFN~/was not 
restored when they were cultured with T-depleted spleen 
cells from SJL mice,  nor was the capacity of MBP-specific 
SJL T  cells  to produce  IFN~/ diminished  when they were 
cultured  with  B10.S  T-depleted  spleen  cells  (data  not 
shown).  Although  the  studies  shown  above  were  per- 
formed with unseparated LNC or purified T  cells, identical 
results were observed when highly purified CD4+  T  cells 
were stimulated  with MBP  in the  presence  of T-depleted 
spleen cells from normal animals. 
The  inability  of B10.S  LNC  to  produce  IFN~/  in  re- 
sponse to MBP was antigen-specific as primed B10.S LNCs 
produced  significant  quantities  of IFN~/  on both  primary 
and secondary in vitro stimulation with a peptide of Influ- 
enza A virus nucleoprotein, NP260_283, previously shown to 
be highly immunogenic in this strain (19)  (Fig. 2, A  and B). 
Primed  B10.S  LNC  also  produced  as  much  IFN'y  as 
primed SJL LNC when stimulated in vitro with PPD (data 
not shown). 
Reconstitution  of the Capacity of MBP-primed BIO.S LNCs 
to Produce IFNy by Treatment with IL- 12.  As IL-12 has been 
shown to play a critical role in the induction of IFN~/pro- 
duction in response to several pathogens, we attempted  to 
induce IFN~/production by MBP-primed B10.S T  cells by 
adding IL-12 to the primary in vitro cultures.  Surprisingly, 
the  addition  of IL-12 resulted  in substantial  production of 
IFN~/in the secondary cultures that was equal to or greater 
than that produced by LN cells  from SJL mice on second- 
ary in vitro challenge. The presence of neutralizing mAb to 
IFN~/did not compromise the ability of IL-12 to promote 
IFN~/production on subsequent  challenge,  suggesting that 
the effect of IL-12 is direct and not mediated by the IFN'y 
it induces.  Furthermore,  the  addition  of IFN~/ to the pri- 
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Figure 3.  Exposure of MBP-reactive LNCs from B10.S mice to IL-12 
promotes IFN',/production  on subsequent antigenic challenge. LN cells 
from MBP-primed B10.S mice were cultured for 4 d in the presence of 
MBP and the cultures were supplemented with the reagents listed in the 
figure. All cultures were then harvested, washed, and restimulated with MBP 
alone and IFN3, production measured after 48 h. kesults are representative 
of  four experiments each using LNCs pooled from five or more mice. 
mary cultures failed to prime for its own synthesis (Fig. 3). 
No  enhancement  of IFN~/  production  in  secondary  cul- 
tures  was  seen  when  either  anti-IL-4 or anti-IL-10 were 
used together with IL-12 in the primary cultures (Fig. 3). 
Encephalitogenicity  of IL-12-treated  BIO.S  and  SJL  LNC. 
The capacity of LN cells  from MBP-primed mice to trans- 
fer EAE to normal adoptive recipients is dependent on re- 
stimulation of the cells in culture. However, the critical pa- 
rameters  that  permit  in  vitro  stimulated  cells  to  induce 
disease have not been fully elucidated. Although the induc- 
tion  of IFN-/  production  by MBP-specific  B10.S  T  cells 
with IL-12 is of interest,  it is not clear if the production of 
IFN~/per se relates to the capacity ofMBP-specific effector 
cells  to induce EAE in vivo. We therefore transferred  SJL 
and B10.S T  cells  that had been cultured with MBP alone 
or B10.S T  cells which had been cultured with MBP in the 
presence of IL-12 to naive recipients and monitored them 
for  the  induction  of EAE.  MBP-reactive  cells  from  SJL 
mice  transferred  moderate  to  severe  relapsing-remitting 
EAE with  100% incidence,  while no disease  was observed 
in recipients ofMBP-reactive T  cells from B10.S mice dur- 
ing a  40  d  follow-up period.  More  importantly,  B10.S  T 
cells that had been cultured with MBP and IL-12 acquired 
the ability to induce EAE upon adoptive transfer.  The re- 
sultant  disease  occurred at  100% incidence,  but was not as 
severe as that induced by SJL LNC. The induction of EAE 
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EAE 
Primary  Mean 
culture  Disease  peak  Disease 
Strain*  conditions  incidence  severity  course  ~ 
SJL  MBP  100%  3.5  relapsing 
B10.S  MBP  0%  N/A  N/A 
B10.S  MBP +  IL-12  100%  2.25  monophasic 
B10.S  NP26o_283  +  IL-12  0%  0  N/A 
*LN cells from antigen-primed B10.S or SJL mice were cultured with 
the indicated antigen in the presence or absence oflL-I 2 (20 ng/ml) for 
4 d. The cells were then washed and injected (3.5 ￿  107 cells intraperi- 
toneal per mouse) into naive syngeneic recipients. Animals were moni- 
tored daily for neurological signs. Results shown are representative of 
four experiments performed with five mice in each group. 
*Average day of disease onset was 8.2 d for B10.S nfice and 7.6 d for 
SJL mice. 
was absolutely dependent on the presence of MBP-specific 
T  cells  as B10.S LNCs sensitized to NP260_283 and exposed 
to IL-12 do not induce EAE (Table  1). 
Discussion 
Multiple  genetic factors control the susceptibility of ex- 
perimental  animals  and  man  to  autoimmune  diseases.  Al- 
though  the  MHC  plays  a  major  role  in  determining  the 
susceptibility of rodents to EAE, our comparison of the fac- 
tors responsible for the induction of EAE in the B10.S and 
SJL  strains  which  both  bear  H-2  ~ has  defined  a  critical, 
non-MHC related, step in the activation cascade of autore- 
active T  cells that is defective in the B10.S mouse. We ini- 
tially  reasoned  that  resistance  of B10.S  mouse  to  MBP- 
induced EAE was mediated  at  the  level of the  T  cell  and 
APC and was not due to factors peripheral  to the immune 
reaction,  such  as  the  impermeability  of the  blood-brain 
barrier or resilience of the oligodendrocyte to autoimmune 
attack, as B10.PL (H-2 ~) mice are readily susceptible to in- 
duction of EAE (4, 20). Hence, there is no characteristic of 
the B10 background which prevents manifestations of EAE 
if functional encephalitogenic T  cells  are present and prop- 
erly primed. We found that the distinguishing characteristic 
of the B10.S immune response to intact MBP, as well as to 
MBP87q06,  was  the  failure  of primed  T  cells  to  produce 
IFNy in  vitro  in  the  presence  of a  vigorous  IL-2-driven 
antigen-specific proliferative  response.  This failure  to pro- 
duce  IFNy in  response  to  MBP  was  antigen-specific  and 
was not secondary to an ongoing Th2 response. 
MBP-reactive  B10.S  LN  cells  acquired  the  ability  to 
produce IFNy upon exposure to IL-12 during primary ex 
vivo challenge with antigen.  Furthermore,  this  ability was 
retained  upon  subsequent  antigenic  challenge  in  the  ab- 
sence  of IL-12.  Concomitantly,  exposure  to  IL-12  un- 
masked the latent potential of these T  cells  to induce EAE 
on adoptive transfer.  It is not clear whether the acquisition 
of the  capacity to produce  IFNy was  directly responsible 
for  encephalitogenicity  of the  IL-12-treated  T  cells.  It is 
possible that IL-12 has an effect on T  cells in addition to its 
well  characterized  ability  to  prime  for  IFNy  production 
that  is  critical  in  conferring  encephalitogenicity.  Indeed, 
previous studies have raised the possibility that endogenous 
IL-12 might play a role in the pathogenesis of EAE by in- 
ducing  the  upregulation  of adhesion  molecules  (9).  The 
role ofIFN~/in the pathogenesis of EAE is not well under- 
stood  as  attempts  to  assess  the  effect  of neutralizing  anti- 
bodies  to  IFN',/ on the  disease  have yielded contradictory 
results  (21-23)  and mice of a susceptible  strain with a dis- 
rupted  IFN~ gene still  manifest clinical signs of EAE after 
transfer of MBP-reactive cells  (24).  Hence, although IFNy 
might play an integral  role  in  establishing  or perpetuating 
the CNS inflammation characteristic  of EAE, its presence is 
not essential and probably can be compensated by produc- 
tion of other proinflammatory cytokines. The induction of 
IFN'y production by IL-12 may thus simply serve as a sur- 
rogate  marker  of encephalitogenicity.  We  cannot  as  yet 
conclude that reconstitution ofencephalitogenicity by treat- 
ment of primed B10.S T  cells with IL-12 is indicative of a 
critical role for this cytokine in the induction of IFNy pro- 
duction in vivo as studies  with neutralizing anti-IL-12 re- 
agents in vivo are still in progress. 
In  conclusion,  we  have  found  that  exposure  to  IL-12 
unmasks  a latent  capacity of MBP-reactive  T  cells  from a 
resistant strain to transfer EAE. These findings have impor- 
tant imphcations for the use oflL-12 or antagonists to IL-12 
for  therapeutic  purposes.  Use  of IL-12  as  an  adjunct  in 
anti-tumor  therapy or as  a  component  of a vaccine could 
trigger  an  autoimmune  syndrome  in  genetically  predis- 
posed individuals.  Our results also suggest that the associa- 
tion  between  intercurrent  infections  and  presentation  or 
relapse ofautoimmune diseases,  including multiple sclerosis 
(25, 26), may he secondary to IL-12 production in response 
to  pathogens.  On  the  other  hand,  our  data  support  the 
view that antagonists  to IL-12 may have therapeutic  value 
in the  treatment  of inflammatory autoimmune  diseases  by 
inhibiting the activation and/or action ofThl  T  cells. 
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